Van Hulzen Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Van Hulzen Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-31	Closed	-$1.12K	–	1009
2024 Q4	$1.12K	Buy	+31	New	+$1.09K	﹤0.01%	1019
2020 Q1	–	Sell	-14,813	Closed	-$351K	–	298
2019 Q4	$351K	Buy	14,813 +416	+3%	+$10.1K	0.07%	198
2019 Q3	$396K	Sell	14,397 -1,734	-11%	-$51.4K	0.08%	171
2019 Q2	$534K	Buy	16,131 +1,972	+14%	+$67.6K	0.12%	124
2019 Q1	$496K	Buy	14,159 +960	+7%	+$35.7K	0.13%	111
2018 Q4	$438K	Buy	13,199 +1,789	+16%	+$76.9K	0.13%	122
2018 Q3	$574K	Buy	11,410 +5,275	+86%	+$260K	0.15%	109
2018 Q2	$367K	Buy	+6,135	New	+$318K	0.11%	126

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Van Hulzen Asset Management's SUPN Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 31 shares — an estimated $1.12K sold.

Van Hulzen Asset Management first reported a position in SUPN in Q2 2018 and held it in 8 quarters. The position peaked at $574K in Q3 2018. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

Van Hulzen Asset Management reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Van Hulzen Asset Management sold 31 Supernus Pharmaceuticals shares in Q1 2025, an estimated $1.12K.
Van Hulzen Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Van Hulzen Asset Management's Supernus Pharmaceuticals position peaked at $574K in Q3 2018.
295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.